Who are β-1,3/1,6-D-glucan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Interferon-Alpha, PAD combination, BG00012 (DMF), Drug: Carfilzomib + Lenalidomide + Dexamethasone, histamine dihydrochloride and IL-2, Single Dose of Hydroxychloroquine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/1-3-1-6-d-glucan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

β-1,3/1,6-D-glucan — Competitive Intelligence Brief

β-1,3/1,6-D-glucan (β-1,3/1,6-D-glucan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator; biological response modifier. Area: Immunology; Infectious Disease.

marketed Immunomodulator; biological response modifier Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3) Immunology; Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

β-1,3/1,6-D-glucan (β-1,3/1,6-D-glucan) — Al-Azhar University. β-1,3/1,6-D-glucan activates innate immune cells by binding to pattern recognition receptors, enhancing immune response and antimicrobial activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
β-1,3/1,6-D-glucan TARGET	β-1,3/1,6-D-glucan	Al-Azhar University	marketed	Immunomodulator; biological response modifier	Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3)
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
BG00012 (DMF)	BG00012 (DMF)	Biogen	marketed	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor
Single Dose of Hydroxychloroquine	Single Dose of Hydroxychloroquine	Shahid Beheshti University of Medical Sciences	marketed	Antimalarial immunomodulator	Toll-like receptors (TLR); lysosomal pH modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator; biological response modifier class)

Al-Azhar University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). β-1,3/1,6-D-glucan — Competitive Intelligence Brief. https://druglandscape.com/ci/1-3-1-6-d-glucan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab